Arnold Bayer, MD
Investigator, The Lundquist Institute
Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA
Recent and/or Significant Publications
- Bayer A.S., A.L. Cheung, N.N. Mishra, A. Rubio, S-J Yang. Dysregulation of mprF and dltABCD expression among daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 71:2100-2104, Aug 2016.
- Bayer AS, Xiong YQ. Redeploying B-lactams against Staphylococcus aureus: Repurposing with a purpose. J Infect Dis 215:11-13; Jan 2017.
- Park J-H, Mishra NM, Kang K-M, Lee G-Y, Yang S-J, Bayer AS. Impact of multiple single-nucleotide polymorphisms within mprF on daptomycin-resistance in Staphylococcus aureus. Microbial Drug Resistance (Jan 2018).
- Zapata B, Alvarez DN, Farah S, Garcia-de-la-Maria C, Miro JM, Sakoulas G, Bayer AS, Mishra NN. Prevention of high-level daptomycin-resistance emergence in vitro in Streptococcus mitis-oralis by using combination antimicrobial strategies. Curr Microbiol. (April 2018)
Bacterial pathogenesis; Relationships of host defense peptides to endovascular infections
Research DescriptionDr. Bayer's research focuses on bacterial pathogenesis, antibiotic resistance, animal models of infection, and therapeutic optimization as it relates to endovascular infections. His lab studies how the human body responds to infection and builds up resistance to antibiotics. His main area of focus is the expression of key virulence factors and genes which enhance the ability of Staphylococcus aureus to cause endovascular infections and resist antibiotics. Additionally, Dr. Bayer is investigating the mechanisms by which platelet peptides kill common blood stream pathogens, and the genetic mechanisms by which certain strains of bacteria develop resistance and cross-resistance to antibiotics. The ultimate goal of his research is to develop strategies to effectively circumvent pathogens as well as drug resistances.
- MD, 1970, Temple University School of Medicine